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Abstract
Introduction and objective. Chronic obstructive pulmonary disease (COPD) is often accompanied by lung cancer. Among 
the genes that may play a role in the occurrence of COPD and lung cancer are those encoding the proteolytic enzymes, such 
as matrix metalloproteinases (MMPs) and their tissue inhibitors. The objective of this study was to find MMPs-associated 
markers useful in the identification of COPD subjects with increased susceptibility to developing lung cancer.   
Materials and methods. We compared the frequency of single nucleotide polymorphisms in genes coding for matrix 
proteinases (MMP1, MMP2, MMP3, MMP9, MMP12) as well as tissue inhibitor of metalloproteinases (TIMP1) in two groups of 
subjects: COPD patients (54 subjects) and COPD patients diagnosed for lung cancer occurrence (53 subjects).The levels of 
the respective proteins in blood serum were also analyzed.   
Results. The frequencies of 2 genotypes, MMP3 rs3025058 and MMP3 rs678815, were significantly different between the 
studied groups. In both cases, more heterozygotes and less homozygotes (both types) were observed in the COPD group 
than in the COPD + cancer group. A significantly higher TIMP1 level in blood serum was observed in the COPD + cancer 
group than in the COPD group. There were no statistically significant differences in MMPs blood levels between the studied 
groups. In addition, no genotype-associated differences in TIMP1 or MMPs blood levels were observed.   
Conclusions. Homozygocity for MMP3 rs3025058 and rs678815 polymorphisms is a potential marker of enhanced susceptibility 
to lung cancer development among COPD subjects.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is 
characterized by an airflow limitation that is not fully 
reversible, usually progressive and associated with an 
abnormal inflammatory response to noxious particles or 
gases. The main cause of COPD is cigarette smoking; other 
causes, such as outdoor air pollution, occupational exposure 
to dust and fumes, previous tuberculosis, childhood asthma 
and childhood respiratory infections, might increase the 
risk of COPD and lead to disease in nonsmokers [1]. Patients 
with COPD are at increased risk for both the development 
of primary lung cancer and poor outcome after lung cancer 
diagnosis and treatment. The association between COPD and 
lung cancer has been reported in numerous studies [reviewed 
in 2–6] and is independent of age or smoking habit [7].
Smokers expose their bronchial epithelial cells to oxidants 
and reactive oxygen species (ROS), which induce oxidative 
stress. The cellular response that follows depends on the 
activation of the NF-κB and other transcription factors, and 
on the subsequent transactivation of inflammation-related 
genes. This initiates several signaling pathways depending 
on both genetic and epigenetic factors which, to some extent, 
overlap in the COPD and lung cancer. Chronic inflammation 
due to cytokine release and the resulting immune response 
contribute to both pathogenic processes. ROS and cigarette 
smoke components are able to induce DNA damage. The 
consequence is genomic instability, a factor sufficient for 
the development of cancer, reinforced by aberrant airway 
epithelial and matrix remodeling, epithelial-mesenchymal 
transition (EMT) and apoptosis [reviewed in 2, 5, 6]. At 
a certain stage, one tendency predominates: either the 
aggravating COPD conditions or the pre-cancerous pathway.
It is to be expected that the fate of individual subjects 
depends to some extent on their genetic predispositions. 
Indeed, twin studies showed that lung cancer susceptibility 
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is inherited in about 15–25% of cases, whereas COPD is 
inherited in 40–77% [6]. Hence, the recent studies seek to 
define the genetic susceptibility factors that contribute to the 
individual susceptibility to COPD and/or lung cancer. So far, 
the only gene that has been definitively proved to influence 
COPD susceptibility is SERPINA1 that encodes α1-antitrypsin 
[8]. Most of the candidate gene studies reporting genetic 
associations with COPD have not been consistently replicated, 
making it difficult to draw reliable conclusions. In the study 
performed by Castaldi et al. [9], 27 genetic variants were 
found to have adequate data for quantitative meta-analysis, 
and 4 among them were significantly associated with COPD 
susceptibility: GSTM1 null variant, TGFB1 rs1800470, TNF 
rs1800629 and SOD3 rs1799896. Genome-wide association 
studies found regions and genes which partly overlap in both 
COPD and lung cancer, and correspond to the pathogenic 
pathways mentioned above [reviewed in 2, 5, 6]. This allows 
for the seeking of an association between single nucleotide 
polymorphisms (SNPs) in the critical genes. A list of 
candidate SNPs examined in 12 genes and the respective 
source information can be found in the paper by Young et al. 
[10]. In that study, the control group of ‘resistant smokers’ 
was compared with COPD and lung cancer groups.
However, since not all COPD subjects develop lung cancer, it 
is important to identify the factors that determine the individual 
cancer susceptibility/resistance in this group. Therefore, a 
comparison of the frequency of several SNPs in 2 groups of 
subjects: patients with COPD and patients with COPD + lung 
cancer was carried out. The SNPs under study were located in 
genes engaged in tissue remodeling that code the following 
matrix metalloproteinases (MMPs) and their inhibitors: matrix 
metalloproteinase 1 (MMP1), matrix metalloproteinase 2 
(MMP2), matrix metalloproteinase 3 (MMP3), matrix 
metalloproteinase 9 (MMP9), matrix metalloproteinase 12 
(MMP12), tissue inhibitor of metalloproteinases 1 (TIMP1) 
[11–18]. In addition to SNPs, the blood serum levels of the 
respective proteins were also analyzed.
MATERIALS AND METHOD
DNA isolation and genotyping. Genomic DNA was isolated 
from whole blood using QIAamp DNA Blood Mini Kit 
(Qiagen) according to the manufacturer’s protocol. Certain 
polymorphisms were assessed by the polymerase chain 
reaction-restriction fragment length polymorphism (PCR-
RFLP) technique. The PCR and RFLP conditions, together 
with the respective references, are presented in Table1. 
Other polymorphisms were assessed using TaqMan® SNP 
Genotyping Assays (Life Technologies) (Tab. 2). Thermal 
cycling was performed on the 7500 Real-Time PCR System 
(Life Technologies) using 100 ng DNA as a template. The 
initial denaturation cycle was at 95  °C for 10 minutes, 
followed by 40 cycles of 95 °C for 15 seconds and 60 °C for 
1 minute. The data were collected and analysed using SDS 
2.4 software (Life Technologies).
Estimation of MMPs and TIMP1 levels. The levels of TIMP1, 
MMP1, MMP2, MMP3, MMP9 proteins in the serum samples 
were determined by the following ELISA tests according to 
the manufacturer’s protocols: TIMP1, active and pro-MMP2 
(total MMP2) Quantikine ELISA Kit (R&D System Inc.); 
MMP1, MMP 3 and MMP9 (Merck Millipore – Calbiochem).
Statistical analysis. Differences in the protein levels in the 
serum between the subjects with COPD and those with 
COPD and lung cancer were analysed by Mann-Whitney 
U-test. The distributions of genotypes in the studied groups 
were compared using χ2 test. In all tests significance was 
accepted at p<0.05. All statistical analyses were performed 
using Statistica 7 software (StatSoft).
RESULTS
The COPD + lung cancer (53 patients) and COPD-only (54 
patients) groups were recruited among the clinic patients 
normalized according to gender, age, smoking habit and 
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Table 1. PCR primers and RFLP conditions for polymorphisms assessed by PCR-RFLP technique
Gene Polymorphism PCR primers and annealing temperature (Ta)
PCR product 
size
Restriction enzyme
Fragments identifying 
genotypes (base pairs)
Reference
MMP1 -1607 1G/2G rs1799750
F 5‘-TGACTTTTAAAACATAGTCTATGTTCA-3‘
R 5‘-TCTTGGATTGATTTGAGATAAGTCATAGC-3‘
Ta = 53°C
269 bp AluI (Fermentas)
1G/1G = 241 + 28
1G/2G = 269 + 241 + 28
2G/2G = 269
[41]
MMP3 6A/5A rs3025058
F 5‘-GGTTCTCCATTCCTTTGATGGGGGGAAAGA-3‘
R 5‘-CTTCCTGGAATTCACATCACTGCCACCACT-3‘
Ta = 63°C
129 bp PsyI (Fermentas)
6A/6A = 129
6A/5A = 129 + 97 + 32
5A/5A = 97 + 32
[42]
MMP9 -1562 C/T rs3918242
F 5‘-GCCTGGCACATAGTAGGCCC-3‘
R 5‘-CTTCCTAGCCAGCCGGCATC -3‘
Ta = 65°C
435 bp PaeI (Fermentas)
C/C = 435
C/T = 435 + 247 + 188
T/T = 247 + 188
[43]
MMP12
-82 A/G rs2276109
F 5‘-GAGATAGTCAAGGGATGATATCAGC-3‘
R 5‘-AAGAGCTCCAGAAGCAGTGG-3‘
Ta = 60°C
199 bp PvuII (Fermentas)
A/A = 199
A/G = 199 + 175 + 24
G/G = 175 + 24
[44]
Asn357Ser rs652438
F 5‘-GGGATAATTTGGCTCTGGTCTTCAA-3‘
R 5‘-CCATGGGAACCATAGAAAAGA-3‘
Ta = 55°C
204 bp MunI (Fermentas)
Asn/Asn = 180 + 24
Asn/Ser = 204 + 180 + 24
Ser/Ser = 204
[44]
Table 2. TaqMan SNP Genotyping Assays used in the study
Gene Polymorphism TaqMan® SNP Genotyping Assay ID
TIMP1 A/G rs6609533 C___2459015_10
MMP1 C/T rs1938901 C___3012119_30
MMP2
C/T rs1030868 C___3225949_1_
A/C rs7201 C___3225976_10
MMP3 C/G rs678815 C___3047716_10
MMP9 A/T rs3918241 C__29689865_10
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diagnosed disease. The detailed characteristics of the subject 
groups were presented in a previous paper [19].
Genotype distribution. The TIMP1 and MMPs genotypes 
distribution for COPD and COPD + cancer groups are 
shown in Table 3. The frequencies of both MMP3 genotypes 
were significantly different between the studied groups. 
In both cases, more heterozygotes and less homozygotes 
(both types) were observed in the COPD group than in the 
COPD + cancer group. In the case of MMP12 rs2276109 
polymorphism, a higher frequency of G allele in the COPD 
+ cancer group was observed, but this tendency was not 
statistically significant (p=0.054). There were no statistically 
significant differences between the groups for the other MMP 
or TIMP1 polymorphisms.
TIMP1 and MMP’s levels in blood serum. The blood serum 
levels of TIMP1 and MMPs were assessed using dedicated 
ELISA kits. A significantly higher TIMP1 level was observed 
in the COPD + cancer group in comparison with the 
COPD group (Fig. 1). There were no statistically significant 
differences in MMPs levels between the studied groups 
(Fig. 2). In addition, no genotype-associated differences in 
TIMP1 or MMPs levels were observed (data not shown).
DISCUSSION
A recent report indicates that previous lung disease (chronic 
bronchitis, emphysema, pneumonia, and tuberculosis) 
influences the lung cancer risk independently of smoking 
habit, and that these diseases are important for estimating 
individual risk of lung cancer [20]. On the other hand, 
Gierada et al. [21] reported a lack of association between 
emphysema and lung cancer. Nevertheless, the airway 
epithelial damage caused by exposure to cigarette smoke 
and the consequent inflammation, seem to be important 
factors in the development of tissue remodeling, dysfunction 
of apoptosis and promotion of angiogenesis.
Among a wide range of genes that may play a role in the 
occurrence of COPD and lung cancer are those encoding 
the proteolytic enzymes, such as matrix metalloproteinases, 
and their tissue inhibitors. MMPs are involved in a stromal 
connective tissue remodeling in inflammatory processes 
and necrosis, and facilitate angiogenesis and tumour growth 
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Table 3. Distribution of genotypes in the studied groups of patients. The results for the 
polymorphisms marked with asterisks were published in the previous paper [19]
Genotype COPD + cancer n=53 (%)
COPD
n=54 (%)
χ2 test
TIMP1 rs6609533
G/G 28 (52.83) 27 (50.00)
p=0.770
A/G 25 (47.17) 27 (50.00)
MMP1 rs1799750*
1G/1G 12 (22.64) 17 (31.48)
p=0.492 1G/2G 26 (49.06) 21 (38.89)
2G/2G 15 (28.30) 16 (29.63)
MMP1 rs1938901
C/C 27 (50.94) 28 (51.85)
p=0.741 C/T 21 (39.62) 23 (42.59)
T/T 5 (9.43) 3 (5.56)
MMP2 rs1030868
C/C 23 (43.40) 24 (44.44)
p=0.432 C/T 22 (41.51) 26 (48.15)
T/T 8 (15.09) 4 (7.41)
MMP2 rs7201
A/A 18 (33.96) 21 (38.89)
p=0.859 A/C 25 (47.17) 23 (42.59)
C/C 10 (18.87) 10 (18.52)
MMP3 rs3025058*
5A/5A 16 (30.19) 9 (16.67)
p=0.006 5A/6A 19 (35.85) 36 (66.67)
6A/6A 18 (33.96) 9 (16.67)
MMP3 rs678815
G/G 16 (30.19) 11 (20.37)
p=0.017 C/G 19 (35.85) 34 (62.96)
C/C 18 (33.96) 9 (16.67)
MMP9 rs3918242*
C/C 42 (79.25) 40 (74.07)
p=0.547 C/T 11 (20.75) 13 (24.07)
T/T 0 (0) 1 (1.85)
MMP9 rs3918241
T/T 42 (79.25) 36 (66.67)
p=0.254 A/T 11 (20.75) 17 (31.48)
A/A 0 (0) 1 (1.85)
MMP12 rs652438*
Asn/Asn 51 (96.23) 49 (90.74)
p=0.251
Asn/Ser 2 (3.77) 5 (9.26)
MMP12 rs2276109*
A/A 36 (67.92) 46 (85.19)
p=0.054 A/G 14 (26.42) 8 (14.81)
G/G 3 (5.66) 0 (0)
Figure 1. Box plots of mean TIMP1 levels in blood serum of the 2 groups of subjects: 
with COPD or COPD and lung cancer. In the box plots, the middle square represents 
the mean, the boxes denote standard error and the whiskers denote standard 
deviation. Significantly different in Mann-Whitney U-test, p < 0.01
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[reviewed in 11, 13–15, 22, 23]; e.g. MMP9 and MMP12 
belong to the markers of epithelial-mesenchymal transition 
[24, 25] that is involved in tumour growth [26], and COPD 
progression.
In the majority of studies, the significance of various MMPs 
polymorphisms for lung cancer risk or COPD was estimated 
by comparing healthy subjects with COPD or cancer patients. 
Overexpression of MMP1 was associated with tumour 
invasion and metastasis formation [27]. Su et al. suggested 
that the MMP1 polymorphism -1607 1G/2G rs1799750 and 
certain haplotypes of MMP3 and MMP12 may lead to an 
increased risk of lung cancer among non-smoking males [17, 
18]. MMP1 -1607 1G/2G rs1799750 polymorphism in relation 
to lung cancer risk was also examined by other authors and 
found to be significantly associated [28, 29]. Associations 
between MMP2 C735T and C1306T polymorphisms and lung 
cancer risk were found in Asians but not in Caucasians [30]. 
In the study performed by Peng et al., MMP2 rs2285053 T 
allele was associated with lower risk of lung cancer, whereas 
for all examined cancer types, MMP2 rs243865, MMP2 
rs2285053 and MMP7 rs11568818 were supposed to play 
allele-specific roles in cancer development [31]. According 
to this analysis, MMP9 rs3918242 may not be a major risk 
factor for most cancer types [31]. However, in another study, 
the same MMP9 rs3918242 polymorphism was associated 
with lower risk of lung cancer [32], similar to MMP8 +17C/G 
rs2155052 polymorphism [33] and MMP2 C1306T or C735T 
[34]. Also, MMP9 P574R and R279Q polymorphisms were 
indicated as potential biomarkers for lung cancer and 
metastasis [35].
Whereas these studies are warranted by a small number 
of subjects and require confirmation in a larger population, 
they also suggest the important role of MMPs as initiators 
of carcinogenesis in lung cancer. They also point to the 
important role of the tissue inhibitors of metalloproteinases, 
alpha 1-antitrypsin, alpha2-macroglobulin and other protease 
inhibitors, which modulate the proteinases activity [8, 23].
In contrast to the above mentioned studies, in the 
presented study comparison was made between the 
occurrence of the MMPs and TIMP1 polymorphisms in 
COPD patients and COPD patients developing lung cancer. 
Among the SNPs examined (Tab. 3), the only difference 
between the subject groups was found in the distribution 
of the two MMP3 polymorphic alleles (MMP3 rs3025058 
and MMP3 rs678815). In both cases, more heterozygotes 
and less homozygotes (both types) were observed in the 
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Figure 2. Box plots of mean MMPs levels in blood serum in the 2 groups of subjects: with COPD or COPD and lung cancer. (A) MMP1; (B) MMP2; (C) MMP3; (D) MMP9. In 
the box plots, the middle square represents the mean, the boxes denote standard error and the whiskers denote standard deviation. The differences are not statistically 
significant
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COPD group than in the COPD + cancer group. This is 
compatible with the notion that heterozygocity for MMP3 
polymorphisms reduces the risk of cancer, a phenomenon 
called ‘heterozygote advantage’. According to Sellis et al., 
the heterozygote advantage is displayed by ‘a substantial 
proportion of adaptive mutations’[36]. This effect stems from 
the susceptibility of heterozygotes to the invasion of new 
adaptive mutations.
Interestingly, MMP3 (also known as stromelysin2) belongs 
to proteases that are preferentially inhibited by TIMP1 [13]. A 
significantly higher TIMP1 level in blood serum was observed 
in the COPD + cancer group than in the COPD group (Fig. 1). 
As MMPs are involved in cancer growth and metastasis, 
their inhibitors seem to be suitable candidates for therapeutic 
factors [37, 38]. Hence, TIMP1 is typically associated with the 
inhibition of MMP induced cancer cell invasion. However, 
TIMP1 is overexpressed in many malignancies and alters 
the expression of approximately 600 genes in vivo, including 
MMP1 and MMP13 [39]. In parallel, the growth-stimulating 
function of TIMP1 has been described and explained in 
molecular terms [40]. Therefore, the high TIMP1 level found 
in subjects from the COPD + cancer group most probably 
reflects the progress of the malignancy.
CONCLUSIONS
The results of the presented study suggest that the homozygocity 
for MMP3 rs3025058 and rs678815 polymorhisms is a 
potential marker of enhanced susceptibility to lung cancer 
development among COPD subjects. More extensive study 
including a larger cohort of patients is needed to confirm 
this relationship.
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